NCI has extended the Blanket Purchase Agreement (BPA), originally signed with ITSIBIO in 2005, until 2010. This highly successful BPA which is managed by SAIC-Frederick, allows all NCI researchers to purchase genomics, proteomics and mass spectrometry services, and consumables from ITSIBIO at a pre-negotiated price. The BPA streamlines the process of outsourcing analytical support and locks-in lower prices for all investigators by leveraging economy of scale. Because the BPA contains legally binding confidentiality and non-disclosure clauses, researchers can fully discuss their experiments with the confidence that their ideas and scientific results will be safe and protected to the full extent required by law.
ITSIBIO receives Human Subject Research and ICH-GCP Certification.
ITSIBIO has received the Human Subject Research and International Conference on Harmonization (ICH) Good Clinical Practice (GCP) certifications. ICH-GCP brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry to ensure protection of human subjects and allow a more economical use of human, animal and material resources, and the elimination of unnecessary delay in the global development and availability of new medicines whilst maintaining safeguards on quality, safety and efficacy, and regulatory obligations to protect public healthÂ. ICH-GCP facilitates the dissemination and communication of information on harmonized guidelines, and the use such information/guidelines to encourage the implementation and integration of common standards. This significant milestone means that ITSIBIO’s staffs have a working knowledge of the principles and ethics associated with good clinical practices, understands Good Clinical Practices dictated by FDA (https://www.fda.gov/oc/gcp/regulations.html) and the ICH Requirements for Sponsors, Monitors, and Investigators. ITSIBIO affirms that all projects performed at ITSIBIO will strictly adhere to Use of Human Subject Research and ICH-GCP guidelines to allow the submission of the data for regulatory approval. Both certifications were received through the Collaborative Institution Training Initiative (CITI, https://www.citiprogram.org/).
ITSIBIO signs agreement with BioConsult, Jerusalem, Israel.
ITSIBIO has appointed BioConsult, Jerusalem, Israel (https://www.bioconsult.co.il/ ) as the exclusive distributor and representative in Israel. The agreement signed December 2007, gives BioConsult exclusive rights to promote, market and distribute all ITSIBIO products and services in Israel. Clients in Israel can now place orders through BioConsult via phone or by visiting their website.
ITSIBIO signs collaboration agreement with University of the Western Cape, Bellville, South Africa.
ITSIBIO has signed a collaboration agreement with the University of Western Cape Proteomics Research Group. Under the agreement, signed December 2007, both parties will collaborate in the areas of proteomics and sample preparation reagent development.
ITSI-Biosciences signs collaboration and distribution agreement with Innovative Biotech Ltd, Keffi Nigeria.
ITSIBIO enters the Nigerian market by signing a collaboration agreement with Innovative Biotech Limited (IBL), Keffi, Nigeria (www.innovativebiotechng.com). Under the agreement signed November 2007, ITSIBIO and IBL will collaborate to develop diagnostic assays for infectious diseases of national interest to Nigeria and the West African region. A distribution agreement signed in December 2007 during the visit of Simon Agwale, PhD, IBL CEO, to ITSIBIO head office in Johnstown, PA also gives IBL the exclusive rights to market, distribute and support ITSIBIO, Panomics Inc. and GenVault Inc products and services in Nigeria. All orders in the Nigerian market should now be placed through IBL Nigeria.
Bin Ali Medical Supplies appointed distributor for the Middle East market.
ITSIBIO announced today the appointment of Bin Ali Medical Supplies (BAMS), Abu Dhabi, United Arab Emirates (https://www.binalimed.com/) as the exclusive distributor and representative in the Middle East. The agreement signed in October 2007, allows BAMS to promote, market and distribute all ITSIBIO’s products and services in the Middle East. Clients in Middle East can now place orders through BAMS.